Recent News

• 06.10.2025 - Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split
• 05.28.2025 - Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025
• 05.14.2025 - Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations
• 04.29.2025 - Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025
• 04.22.2025 - Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

Recent Filings

• 06.09.2025 - 8-K Current report
• 06.02.2025 - 8-K Current report
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.07.2025 - 4/A Statement of changes in beneficial ownership of securities
• 05.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.29.2025 - EFFECT Notice of Effectiveness
• 04.29.2025 - 424B3 Prospectus [Rule 424(b)(3)]